Azurity’s patents covering Epaned® required that the claimed medicament contain a buffer comprising specific concentrations of citric acid and sodium citrate. In litigation, Azurity conceded that the ...
Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka) has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for the ...
This acquisition includes substantially all of the existing assets and infrastructure at MedXL facilities, such as intellectual property, real estate, manufacturing equipment, and global product ...